Company Overview of BioCurex Inc.
BioCurex, Inc., a development stage company, engages in developing, producing, marketing, and licensing products based on patented and proprietary technology in the area of cancer diagnostics. It develops various product candidates based on RECAF technology. The company offers its RECAF technology in three basic formats, including automated testing in large clinical and hospital laboratories; non-automated or manual testing by clinicians in smaller laboratory settings; and point-of-care rapid test formats for physicians’ offices, and urgent care facilities. It also develops RECAF marker, a cancer marker, which is used in blood tests to detect the presence of cancer in humans and animals. The...
7080 River Road
Richmond, BC V6X 1X5
Founded in 1997
Key Executives for BioCurex Inc.
Chief Executive Officer, President and Director
Corporate Secretary and Director
Compensation as of Fiscal Year 2016.
BioCurex Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of Biocurex
Oct 7 14
An Administrative Law Judge has issued an Initial Decision of Default as to Biocurex, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.
SEC Orders Hearings On Registration Suspension Or Revocation Against BioCurex Inc. For Failure To Make Required Periodic Filings
Sep 4 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of BioCurex Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries